CN110049966A - 氨基甲酰基苯丙氨醇化合物及其用途 - Google Patents
氨基甲酰基苯丙氨醇化合物及其用途 Download PDFInfo
- Publication number
- CN110049966A CN110049966A CN201780075629.4A CN201780075629A CN110049966A CN 110049966 A CN110049966 A CN 110049966A CN 201780075629 A CN201780075629 A CN 201780075629A CN 110049966 A CN110049966 A CN 110049966A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- compound
- carbon atoms
- pharmaceutically acceptable
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/58—Y being a hetero atom
- C07C275/60—Y being an oxygen atom, e.g. allophanic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/66—Y being a hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404917P | 2016-10-06 | 2016-10-06 | |
| US62/404,917 | 2016-10-06 | ||
| PCT/US2017/055598 WO2018067971A1 (en) | 2016-10-06 | 2017-10-06 | Carbamoyl phenylalaninol compounds and uses therof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110049966A true CN110049966A (zh) | 2019-07-23 |
Family
ID=60183122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780075629.4A Pending CN110049966A (zh) | 2016-10-06 | 2017-10-06 | 氨基甲酰基苯丙氨醇化合物及其用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10710958B2 (enExample) |
| EP (2) | EP4316592A3 (enExample) |
| JP (1) | JP7074750B2 (enExample) |
| KR (1) | KR102616545B1 (enExample) |
| CN (1) | CN110049966A (enExample) |
| CA (1) | CA3039045A1 (enExample) |
| ES (1) | ES2964943T3 (enExample) |
| MY (1) | MY202185A (enExample) |
| PH (1) | PH12019500751A1 (enExample) |
| SG (1) | SG11201903076QA (enExample) |
| WO (1) | WO2018067971A1 (enExample) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111094238B (zh) | 2017-07-31 | 2023-06-09 | 杰资制药爱尔兰有限公司 | 氨基甲酰基苯丙氨醇类似物及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015130121A1 (en) * | 2014-02-28 | 2015-09-03 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US6472431B2 (en) | 1998-12-23 | 2002-10-29 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| RU2007119648A (ru) | 2004-10-28 | 2008-12-10 | СК Холдингз Ко. | Способ лечения депрессии |
| ES2435403T3 (es) | 2005-06-08 | 2013-12-19 | Sk Biopharmaceuticals Co., Ltd. | Tratamiento de trastornos del sueño y vigilia |
| US8552060B2 (en) | 2005-06-22 | 2013-10-08 | Sk Biopharmaceuticals Co., Ltd. | Methods for treatment of sexual dysfunction |
| US8741950B2 (en) | 2009-06-22 | 2014-06-03 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| KR101783633B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 섬유근육통 증후군의 치료 방법 |
| EP2496228B1 (en) | 2009-11-06 | 2014-01-15 | SK Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| RU2689984C2 (ru) | 2013-03-13 | 2019-05-30 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Лечение катаплексии |
| KR20160030955A (ko) | 2013-07-12 | 2016-03-21 | 에스케이바이오팜 주식회사 | 금연의 촉진 |
| EP3021838B1 (en) | 2013-07-18 | 2020-05-27 | Jazz Pharmaceuticals Ireland Limited | Treatment for obesity |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
-
2017
- 2017-10-06 CA CA3039045A patent/CA3039045A1/en not_active Abandoned
- 2017-10-06 CN CN201780075629.4A patent/CN110049966A/zh active Pending
- 2017-10-06 WO PCT/US2017/055598 patent/WO2018067971A1/en not_active Ceased
- 2017-10-06 MY MYPI2019001915A patent/MY202185A/en unknown
- 2017-10-06 EP EP23199791.7A patent/EP4316592A3/en active Pending
- 2017-10-06 JP JP2019518480A patent/JP7074750B2/ja active Active
- 2017-10-06 EP EP17790906.6A patent/EP3523275B1/en active Active
- 2017-10-06 KR KR1020197013113A patent/KR102616545B1/ko active Active
- 2017-10-06 ES ES17790906T patent/ES2964943T3/es active Active
- 2017-10-06 US US16/338,925 patent/US10710958B2/en active Active
- 2017-10-06 SG SG11201903076QA patent/SG11201903076QA/en unknown
-
2019
- 2019-04-05 PH PH12019500751A patent/PH12019500751A1/en unknown
-
2020
- 2020-06-03 US US16/891,464 patent/US11149000B2/en active Active
-
2021
- 2021-09-09 US US17/470,063 patent/US11780805B2/en active Active
-
2023
- 2023-09-18 US US18/469,032 patent/US20240018098A1/en not_active Abandoned
-
2024
- 2024-11-05 US US18/937,105 patent/US20250059136A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015130121A1 (en) * | 2014-02-28 | 2015-09-03 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
Non-Patent Citations (2)
| Title |
|---|
| 金国章主编: "《脑内多巴胺》", 30 November 2010, 上海科学技术出版社 * |
| 韩春美主编: "《神经精神病学》", 31 August 2006, 军事医学科学出版社 * |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12128021B1 (en) | 2016-07-22 | 2024-10-29 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263150B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097176B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097175B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12109186B2 (en) | 2016-07-22 | 2024-10-08 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115144B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115145B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115143B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115142B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12239625B2 (en) | 2016-07-22 | 2025-03-04 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12138239B2 (en) | 2016-07-22 | 2024-11-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12144793B2 (en) | 2016-07-22 | 2024-11-19 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263151B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12257223B2 (en) | 2016-07-22 | 2025-03-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186298B2 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226389B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226388B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics |
| US12226377B2 (en) | 2019-03-01 | 2025-02-18 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167992B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167991B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12303478B2 (en) | 2019-03-01 | 2025-05-20 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12295926B1 (en) | 2022-02-07 | 2025-05-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US12551457B1 (en) | 2022-02-07 | 2026-02-17 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200290955A1 (en) | 2020-09-17 |
| EP4316592A3 (en) | 2024-05-01 |
| WO2018067971A1 (en) | 2018-04-12 |
| US10710958B2 (en) | 2020-07-14 |
| EP3523275B1 (en) | 2023-09-27 |
| EP4316592A2 (en) | 2024-02-07 |
| MY202185A (en) | 2024-04-15 |
| JP7074750B2 (ja) | 2022-05-24 |
| PH12019500751A1 (en) | 2019-08-05 |
| US11149000B2 (en) | 2021-10-19 |
| CA3039045A1 (en) | 2018-04-12 |
| US11780805B2 (en) | 2023-10-10 |
| US20220098145A1 (en) | 2022-03-31 |
| ES2964943T3 (es) | 2024-04-10 |
| US20250059136A1 (en) | 2025-02-20 |
| JP2020503246A (ja) | 2020-01-30 |
| KR102616545B1 (ko) | 2023-12-26 |
| US20240018098A1 (en) | 2024-01-18 |
| EP3523275A1 (en) | 2019-08-14 |
| US20190218175A1 (en) | 2019-07-18 |
| KR20190072561A (ko) | 2019-06-25 |
| SG11201903076QA (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11780805B2 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
| JP7642707B2 (ja) | カルバモイルフェニルアラニノール類縁体およびその使用 | |
| ES2261234T5 (es) | Metabolitos de bupropion y metodos de sintesis y uso. | |
| CA2854622A1 (en) | Modulators of opioid receptors and methods of use thereof | |
| CA3210270A1 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| JP2024540583A (ja) | Ｋｖ７．２エンハンサーとしてのピリジン化合物 | |
| CA3232827A1 (en) | Substituted phenylalkylamines | |
| CN116496205B (zh) | 一种卡瑞斯汀的盐及其用途 | |
| NL8100808A (nl) | 2-amino-3-hydroxy(fenyl)methylfenylazijnzuren, hun esters en amiden. | |
| WO2025104490A1 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| HK40003964A (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| JP2025506201A (ja) | 新規なビシクロペンタン誘導体 | |
| TW200946105A (en) | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient | |
| CN111094259A (zh) | 止痛化合物 | |
| RU2477283C1 (ru) | 4,7-ДИМЕТИЛ-2-(2,4,5-ТРИМЕТОКСИФЕНИЛ)-3,4,4a,5,8,8a-ГЕКСАГИДРО-2H-4,8-ЭПОКСИХРОМЕН, ОБЛАДАЮЩИЙ АНАЛЬГЕЗИРУЮЩЕЙ АКТИВНОСТЬЮ | |
| EA043769B1 (ru) | Соли валбеназина и их полиморфы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191213 Address after: Dublin Applicant after: JAZZ PHARMACEUTICALS INC Address before: Hamilton, British Bermuda Applicant before: Jiezi Pharmaceutical International Phase III Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40003964 Country of ref document: HK |